Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
5(50%)
Results Posted
100%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_4
1
10%
Ph phase_1
1
10%
Ph phase_2
1
10%
Ph phase_3
1
10%
Ph early_phase_1
3
30%
Ph not_applicable
3
30%

Phase Distribution

4

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
3(30.0%)
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(7)
Completed(1)
Terminated(2)

Detailed Status

Recruiting3
Active, not recruiting2
Not yet recruiting2
Withdrawn1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (30.0%)
Phase 11 (10.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)
Phase 41 (10.0%)
N/A3 (30.0%)

Trials by Status

withdrawn110%
recruiting330%
active_not_recruiting220%
completed110%
not_yet_recruiting220%
terminated110%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_4

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
not_yet_recruitingnot_applicable

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

NCT07075705
recruitingearly_phase_1

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

NCT07164027
completedphase_1

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

NCT06661902
active_not_recruitingearly_phase_1

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

NCT05160597
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06733350Phase 4

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Recruiting
NCT07075705Not Applicable

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

Not Yet Recruiting
NCT07164027Early Phase 1

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Recruiting
NCT06661902Phase 1

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

Completed
NCT05160597Early Phase 1

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Active Not Recruiting
NCT03234556Not Applicable

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA

Active Not Recruiting
NCT06024772Phase 3

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

Not Yet Recruiting
NCT05852041Early Phase 1

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

Recruiting
NCT02597894Not Applicable

Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy

Withdrawn
NCT01253642Phase 2

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Terminated

All 10 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
10